Suppr超能文献

成人急性髓系白血病中RIC与MAC非清髓性脐血移植的比较:欧洲血液与骨髓移植协会(EBMT)的欧洲脐血库(Eurocord)、急性白血病工作组(ALWP)及慢性白血病工作组(CTIWP)的报告

RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT.

作者信息

Baron Frédéric, Ruggeri Annalisa, Beohou Eric, Labopin Myriam, Sanz Guillermo, Milpied Noel, Michallet Mauricette, Bacigalupo Andrea, Blaise Didier, Sierra Jorge, Socié Gérard, Cornelissen Jan J, Schmid Christoph, Giebel Sebastian, Gorin Norbert-Claude, Esteve Jordi, Ciceri Fabio, Savani Bipin N, Mohty Mohamad, Gluckman Eliane, Nagler Arnon

机构信息

University of Liege, Liege, Belgium.

Eurocord, Hospital Saint Louis, AP-HP, and IUH University Paris VII, Paris, France.

出版信息

Oncotarget. 2016 Jul 12;7(28):43027-43038. doi: 10.18632/oncotarget.9599.

Abstract

Nonrelapse mortality (NRM) is the first cause of treatment failure after unrelated cord blood transplantation (UCBT) following myeloablative conditioning (MAC). In the last decade, reduced-intensity conditioning (RIC) regimens have been developed with the aim of reducing NRM and allowing older patients and those with medical comorbidities to benefit from UCBT. The aim of the current retrospective study was to compare transplantation outcomes of acute myeloid leukemia (AML) patients given UCBT after either RIC or MAC. Data from 894 adults with AML receiving a single or double UCBT as first allograft from 2004 to 2013 at EBMT centers were included in this study. 415 patients were given UCBT after RIC while 479 patients following a MAC. In comparison to MAC recipients, RIC recipients had a similar incidence of neutrophil engraftment and of acute and chronic graft-versus-host disease (GVHD). However, RIC recipients had a higher incidence of disease relapse and a lower NRM, translating to comparable leukemia-free (LFS), GVHD-free, relapse-free survival (GRFS) and overall survival (OS). These observations remained qualitatively similar after adjusting for differences between groups in multivariate analyses. In conclusion, these data suggest that LFS and OS are similar with RIC or with MAC in adults AML patients transplanted with UCBT. These observations could serve as basis for a future prospective randomized study.

摘要

非复发死亡率(NRM)是清髓性预处理(MAC)后非血缘脐血移植(UCBT)治疗失败的首要原因。在过去十年中,为降低NRM并使老年患者及合并内科疾病的患者能够从UCBT中获益,开发了减低强度预处理(RIC)方案。本回顾性研究的目的是比较接受RIC或MAC预处理后行UCBT的急性髓系白血病(AML)患者的移植结局。本研究纳入了2004年至2013年在欧洲血液与骨髓移植协会(EBMT)中心接受单次或双份UCBT作为首次同种异体移植的894例成年AML患者的数据。415例患者接受RIC后行UCBT,479例患者接受MAC后行UCBT。与接受MAC的患者相比,接受RIC的患者中性粒细胞植入、急慢性移植物抗宿主病(GVHD)的发生率相似。然而,接受RIC的患者疾病复发率较高,NRM较低,这导致无白血病生存期(LFS)、无GVHD生存期、无复发生存期(GRFS)和总生存期(OS)相当。在多变量分析中对组间差异进行校正后,这些观察结果在性质上仍然相似。总之这些数据表明,接受UCBT的成年AML患者采用RIC或MAC的LFS和OS相似。这些观察结果可为未来的前瞻性随机研究提供依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1d7/5190005/1a0aab2bc8ca/oncotarget-07-43027-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验